|
Now averaging nearly 500,000 pages viewed per year
9.267
x 52 = 481,884
|
General
Summary |
|
1. |
Host name |
jerrymondo |
|
2. |
Program start time |
Nov 18, 2007 02:43 |
|
3. |
Time of first request |
Aug
4, 2004 11:54 |
|
4. |
Time of last request |
Nov
17, 2007 23:59 |
|
5. |
Time last 7 days lasts until |
Nov
18, 2007 02:43 |
|
6. |
Successful server requests |
1,011,280
Requests |
|
7. |
Successful requests in last 7 days |
9,267 Requests |
|
8. |
Successful requests for pages |
616,702
Requests for pages |
|
9. |
Successful requests for pages in last
7 days |
9,267 Requests
for pages |
Your site had 1213 page views yesterday and 38066 page views so far this month.
There is an
alarming laxity in the production of research, education of public and doctors, and standards of FDA approval for drugs, as
well as the monitoring of safety and effectiveness of drugs. For 2 chapters of
the best book on how big PHARMA has manipulated the above and much more by Doctor Marcia Angell (Harvard Professor and former editor
of New England Journal of Medicine).
Those who have a financial interest in the outcome manipulate the results, Major study finds that all 37 journal articles positive effects over stated; the average was 32%.
STATINS CANCER Link
52% short term
LA Times, Health section, July 21, 2008 -- excerpts
Vytorin, the combination
drug (simvastatin (better known by its commercial name Zocor) and ezetimibe--known as Zetia) prescribed to lower cholesterol,
sustained another blow today, when the author of a major clinical trial announced that the medication had failed to drive
down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process, researchers
in Norway detected a significant blip in cancers in the 1,800 subjects they followed
Today's findings
suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients
taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial.
Among subjects on Vytorin, 102 developed cancers of various kinds.* This
is the second adverse press—the first being in March 08, when the ENHANCE trial found that Vytorin fared no better than
a placebo at reducing plaque buildup on the walls of patients' arteries.* *
Comments
by jk
Simvastatin (Zocor) is off patent. Thus in a scramble for profits a combination drug (on patent) was introduced. Direct to consumer market cost $155 in 07—mainly TV ads.
*
The pressing issue is that since the development of Statins, the very
first animal studies in the 60s it has been known that Statins increase the incidents of cancer. However, nearly all studies done thereafter have not included cancer.
*
Several studies have failed to find a reduction in the build of plaque, even thought the statins including Zocor, reduce
LDL and cholesterol. Few studies include the
principle reason for taking a statin, namely a reduction in the death rate. Claims
for such reduction probably entail a failure to control the contravening variable, aspirin usage. Given a pile of evidence, including the very mechanism of plaque formation, which involves inflammation
process, I must conclude that the use of statins is highly suspect. Given the
harm done including cognitive impairment, weakness, and cancer, if my skepticism is born out, the harm done by statins as
a course of treatment will far surpass that of VIOXX which killed over 200,000 people world wide by accelerating atherosclerosis.
|
